<DOC>
	<DOCNO>NCT01922830</DOCNO>
	<brief_summary>This study randomize clinical trial 6 month probiotic supplement vs. placebo treatment 6 month follow 100 NAFLD patient undergo sleeve gastrectomy surgery . Measurements conduct : baseline , M3 ( 3 month treatment initiation ) , M6 M12 include : abdominal US , Fibroscan , biochemical test , anthropometric measurement , glucose breath test bacterial overgrowth , fecal sample questionnaire demographic detail , quality life , food intake , food tolerance habitual physical activity . 20 subject undergo additional liver-MRI test baseline M6 .</brief_summary>
	<brief_title>Probiotics Microbiota Bariatric Surgery</brief_title>
	<detailed_description>Background : Bariatric surgery effective increasingly common treatment obesity obesity-related comorbidities . Among patient undergo bariatric surgery , many 96 % NAFLD ( Nonalcoholic fatty liver disease ) 25 % NASH ( Nonalcoholic steatohepatitis ) . Intestinal microbiota show play pivotal role host mammalian developmental , immune metabolic function . Alterations gut microbiome , 'dysbiosis ' recently link pathogenesis metabolic disease include obesity , insulin resistance , atherosclerosis liver disease . Recent study show modulation gut microbiota may represent novel way treat prevent NAFLD progression . Bariatric surgery associate major modification microbiota composition , quantity function . Potential mediator gut microbiota probiotic consider safe therapy since microorganism composition find naturally human microflora . To date , lack evidence use probiotic bariatric surgery 1 randomizes clinical trial Roux-en-Y gastric bypass surgery patient . Aims : To evaluate effect 6 month probiotic supplement vs. placebo clinical metabolic parameter patient NAFLD undergo sleeve gastrectomy surgery . Working hypothesis : Modulation gut microbiota probiotic beneficial effect clinical metabolic parameter sleeve gastrectomy patient NAFLD . Methods : A randomized double blind clinical trial 6 month treatment 6 month follow include 2 treatment arm : probiotic placebo . One hundred NAFLD patient undergo sleeve gastrectomy surgery bariatric surgery clinic Tel Aviv Assuta medical center enrol 2013-2016 . Baseline follow evaluation perform Tel-Aviv Sourasky Medical center include : abdominal US ( hepato-renal index-HRI ) , Fibroscan , biochemical test , anthropometric measurement , glucose breath test bacterial overgrowth ( BO ) . Fecal sample collect analyzed gut microbiota utilize 'state art ' molecular method . All patient fill validate questionnaire demographic detail , quality life , food intake , food tolerance habitual physical activity . Measurements conduct : baseline , M3 ( 3 month treatment initiation ) , M6 M12 . 20 subject undergo additional liver-MRI test baseline M6 . Importance study : Almost morbid obese patient NAFLD 25 % NASH , lead major hepatic extra-hepatic complication . Only limited data available concern gut microbiota composition bariatric surgery association weight reduction , metabolic hepatic parameter . Moreover , clinical trial role probiotic administration follow sleeve gastrectomy bariatric surgery hepatic parameter . Probiotic supplement bariatric surgery may improve therapeutic effect surgery hepatic steatosis may improve also biochemical test vitamin ( e.g . B12 ) , inflammatory mediator ( e.g . endotoxin level ) metabolic parameter , reduce bacterial overgrowth enhance weight loss . The study would help develop new treatment approach contribute understand mechanism underlie hepatic , metabolic inflammatory consequence bariatric surgery .</detailed_description>
	<criteria>Subjects 1865 year old BMI &gt; 40 kg/m² BMI &gt; 35 kg/m² comorbidities ( See Appendix 1 Ministry health indication bariatric surgery ) get bariatric commission approval Assuta private hospital undergo sleeve gastrectomy surgery Willingness take probiotic/placebo supplement day 6 month Ultrasound diagnosed NAFLD patient Reading speak Hebrew Subject mental illness cognitive deterioration Use probiotic/antibiotic 3 mount surgery Use antibiotic 1 week study Drug addiction Excessive alcohol consumption ( ≥ 30 g/day men ≥ 20 g/day woman ) Treatment drug know cause hepatic steatosis elevation liver enzyme ( e.g . Corticosteroids , HAART , Amiodarone , high dose estrogen ) ( see Appendix 2 ) Treatment drug supplement may improve hepatic steatosis liver enzyme ( Vitamin E , Milk thistle , ω3 fatty acid , Ursodeoxycholic acid ) 3 month prior initiation study Other cause chronic liver disease ( e.g . viral hepatitis : HBV/HCV + , autoimmune hepatitis , Hemochromatosis , Wilson 's disease ) Diabetic patient treat antidiabetic medication , except diabetic patient treat least 6 month exclusively Metformin stable dose Subjects begin new lipid reduction medication less 6 month prior initiation study Subjects chronic condition could interfere study : active cancer , organ transplant subject , advance kidney liver disease , inflammatory bowel disease systemic inflammatory condition Bariatric surgery past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Sleeve Gastrectomy</keyword>
	<keyword>NAFLD</keyword>
	<keyword>gut microbiot</keyword>
	<keyword>Bariatric surgery</keyword>
</DOC>